TRC160334

TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 can be used for the research of ischemia/reperfusion injury In Vitro TRC160334 (100~400 μΜ; 4 hours; Hep3B cells) results in dose-dependent stabilization of nuclear HIF-1. TRC160334 (75~300 μM; 4 hours; Hep3B cells) results in dose-dependent transcriptional activation of HIF-1. TRC160334 shows a dose-dependent expression of HIF target genes such as EPO and adrenomedullin. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: Hep3B cells Concentration: 100~400 μΜ Incubation Time: 4 hours Result: Resulted in dose-dependent stabilization of nuclear HIF-1. In Vivo TRC160334 (0.1 and 0.3 mg/kg; i.p.) significantly reduces serum creatinine and blood urea nitrogen . TRC160334 (0.3 and 0.6 mg/kg; i.p.) shows reducing trends for acute tubular necrosis . TRC160334 significantly reduces the rise in electrolyte excretion dose dependently. Preischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 6 hours while postischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 12 hours as compared with the respective vehicle control . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Sprague-Dawley male rats (250–300 g) Dosage: 0.1 and 0.3 mg/kg Administration: I.p. Result: Significantly reduced serum creatinine and blood urea nitrogen. Animal Model: Sprague-Dawley male rats (250–300 g) Dosage: 0.3 and 0.6 mg/kg Administration: I.p. Result: Showed reducing trends for acute tubular necrosis. Form:Solid IC50& Target:HIF hydroxylase

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet